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The slow-channel myasthenic syndrome (SCS) is a hereditary disorder of the acetylcholine receptor (AChR) 
of the neuromuscular junction (NMJ) that leads to prolonged AChR channel opening, Ca2+ overload, and 
degeneration of the NMJ. We used an SCS transgenic mouse model to investigate the role of the calcium-acti-
vated protease calpain in the pathogenesis of synaptic dysfunction in SCS. Cleavage of a fluorogenic calpain 
substrate was increased at the NMJ of dissociated muscle fibers. Inhibition of calpain using a calpastatin (CS) 
transgene improved strength and neuromuscular transmission. CS caused a 2-fold increase in the frequency of 
miniature endplate currents (MEPCs) and an increase in NMJ size, but MEPC amplitudes remained reduced. 
Persistent degeneration of the NMJ was associated with localized activation of the non-calpain protease 
caspase-3. This study suggests that calpain may act presynaptically to impair NMJ function in SCS but further 
reveals a role for other cysteine proteases whose inhibition may be of additional therapeutic benefit in SCS 
and other excitotoxic disorders.
*OUSPEVDUJPO
The slow-channel congenital myasthenic syndrome (SCS) is a domi-
nantly inherited neuromuscular disorder characterized by impaired 
neuromuscular transmission and degeneration of the neuromus-
cular junction (NMJ) (1–3). Patients with SCS manifest fatigability 
and progressive weakness of the skeletal muscles, with symptoms 
ranging from eye muscle and mild limb weakness to severe inca-
pacitation and respiratory failure. Ultrastructural study of muscle 
in SCS reveals a focal degenerative and remodeling process selec-
tively localized to the NMJ termed endplate myopathy. This progres-
sive, purely synaptic disease process, in which the cleft is widened 
and nerve terminals are shrunken, is characterized by expansion 
and degeneration of postsynaptic folds as well as degeneration of 
subsynaptic nuclei, mitochondria, and myofibrils (1–4).
The SCS is caused by missense mutations within the genes 
encoding nicotinic acetylcholine receptor (AChR) subunits. The 
mutations alter the AChR channel gating function, causing pro-
longed activation events, persistent synaptic currents, and local-
ized calcium overload at the NMJ, amplified by calcium release 
from intracellular stores (1, 3, 5–10). These changes lead to weak-
ness and impaired neuromuscular transmission through an effect 
on both pre- and postsynaptic determinants of synaptic transmis-
sion, including quantal release, synaptic cleft anatomy, and the 
function and density of postsynaptic AChRs. Expression of sev-
eral distinct AChR mutations characteristic of the SCS in trans-
genic mice reproduces the features of the SCS. The SCS mutation, 
εL269F, expressed in transgenic mice, most closely reproduces the 
clinical syndrome of weakness, fatigability, and impaired neuro-
muscular transmission (9, 10).
Elucidating the biochemical pathways coupling the ionic distur-
bance in SCS to the synaptic degeneration may be of benefit to 
understanding other degenerative disorders of nerve and muscle. 
Activation of endogenous proteolytic enzymes plays a prominent 
role in cell death, in muscular dystrophy, and in neurodegenerative 
diseases (11–13). We previously showed that some forms of the cys-
teine proteases, caspases that play a prominent role in the apoptot-
ic cascade, are locally activated at the NMJ in SCS and in its trans-
genic mouse model (14, 15). Calcium overload of muscle fibers that 
is highly localized to the NMJ in SCS might exhaust calcium buff-
ering reserves and activate the calcium-activated cysteine protease 
calpain. Previous attempts to detect activated calpain polypeptide 
in Western blots in SCS muscle homogenates were unsuccessful, 
perhaps due to the localized nature of the process. In this study we 
employed the enzymatic substrate, t-butoxycarbonyl-Leu-Met-7-
amino-4-chloromethyl-coumarin (BOC-Leu-Met-CMAC), a fluo-
rogenic calpain substrate used to detect calpain-like activity within 
living cells. The nonfluorescent BOC-Leu-Met-CMAC molecule is 
membrane permeable and becomes nondiffusible by enzymatic 
conjugation to thiol groups by glutathione-S-transferase (16). Pro-
teolytic cleavage at the methionine residue releases and unquenches 
the fluorescent membrane-insoluble MAC-thiol moiety.
We investigated the role of calpain in impaired synaptic trans-
mission seen in SCS. We found that calpain activity in muscle 
fibers from εL269F SCS transgenic mice was significantly elevated 
at the NMJ, was dependent on synaptic activity, and diminished 
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to baseline with AChR blockade. Transgenic expression of human 
calpastatin (CS), the natural inhibitor of calpain, in εL269F mice 
reduced calpain to baseline, normalized NMJ size and miniature 
endplate current (MEPC) frequency and improved strength and 
neuromuscular transmission. Persistent endplate myopathy in 
CS-SCS double transgenic mice was associated with ongoing, local-
ized activation of components of the caspase family of cysteine 
proteases, which are not inhibited by CS. These findings provide 
evidence for the role of 2 separate families of cysteine proteases in 
the SCS, for which separate therapeutic strategies for inhibition 
may provide synergistic benefit.
3FTVMUT
Muscle calpain activity is elevated in a transgenic model of SCS. Using 
dissociated muscle fibers from the flexor digitorum brevis (FDB) 
loaded with the fluorogenic calpain substrate BOC-Leu-Met-
CMAC, we compared the fluorescent signal from SCS and control 
fibers taken from mice aged 4–8 months. Many FDB fibers from 
εL269F mice had visibly elevated fluorescence, some with regions 
suggesting intense calpain activity localized to endplate areas (Fig-
ure 1A), while nontransgenic control fibers (WT) had less intense 
fluorescence (Figure 1B). The mean fluorescence signal inten-
sity of εL269F SCS fibers at endplates was approximately 2-fold 
greater than that of WT fibers (Figure 1C; 1,591 ± 72 vs. 815 ± 72; 
n = 10; P < 0.01). We confirmed the specificity of these signals by 
preincubation with vehicle or with a specific peptide inhibitor of 
calpain, calpain inhibitor 1 (CP1). CP1 treatment of εL269F fibers 
led to a significant reduction in calpain activity when compared 
with untreated εL269F fibers (801.6 ± 25; n = 3; P < 0.01). The fluo-
rescence signal of CP1-treated εL269F fibers was similar to that 
of untreated WT (815.1 ± 72; n = 10; P = 0.86), vehicle-treated WT 
(855.3 ± 52; n = 3; P = 0.66), or CP1-treated WT fibers (924 ± 34; 
n = 3; P = 0.27). Pretreatment of εL269F SCS fibers with vehicle had 
no effect on calpain activity (vehicle: 1,593 ± 72, n = 3, vs. untreated: 
1,591 ± 72, n = 10; P = 0.99). These findings indicate that muscle 
fibers from transgenic mice expressing εL269F AChRs have elevated 
calpain activity, particularly in the region of the NMJ.
Calpain activity in slow-channel mouse endplates requires active syn-
apses. Previous studies have shown that Ca2+ accumulates to 
histochemically detectable levels at NMJs in human SCS and in 
εL269F SCS mice and increases within minutes after neuromus-
cular activity, in part due to release from internal stores (1, 10, 
15, 17). Figure 2A shows that these focal Ca2+ accumulations are 
also dependent on intact muscle innervation. The number of end-
plates with accumulations detectable by glyoxal-bis-2-hydroxyanil 
(GBHA) stain was reduced 3-fold by 24 hours after axotomy, from 
47% ± 6.2% to 15% ± 1.3% (P < 0.01; n = 3) and was undetectable 
after 48 hours. Because of the rapid disappearance of the deposits 
of endplate Ca2+ after axotomy, we tested whether calpain activ-
ity in SCS muscle was similarly dependent on muscle innervation. 
Surgical axotomy significantly reduced calpain activity of εL269F 
FDB fibers (Figure 2B; 761 ± 78) by 24 hours but had no effect 
on the contralateral, innervated FDB fibers (1,447 ± 73; n = 3; 
P < 0.01). To insure that axotomy did not activate calpain through 
cell-signaling events caused by nerve retraction or trophic factor 
withdrawal from muscle fibers, we tested the effect of irreversible 
blockade of AChR activation using α-bungarotoxin (αBT) (18). In 
preliminary experiments we established the dose of αBT needed 
to completely block AChRs in the FDB muscle. As with axotomy, 
complete blockade of AChRs in vivo caused a significant reduction 
in calpain activity assessed after 24 hours when compared with 
the untreated contralateral hind limb (Figure 2C; 1,009 ± 84 vs. 
1,600 ± 98; n = 4; P < 0.01). Therefore, increased calpain activation 
in SCS requires continuous activation of mutant AChRs.
A CS transgene normalizes calpain activity in double-transgenic εL269F 
muscle. We hypothesized that increased calpain activity in SCS 
may contribute to the pathogenesis of the SCS. To test the protec-
tive effect of CS in SCS, we bred εL269F mice with mice bearing a 
human CS transgene targeted to skeletal muscle (CS mice) to gen-
erate mice bearing both the SCS and CS transgenes (CS/εL269F 
mice). Transgenic overexpression of CS in mdx mice improved 
dystrophic changes (19). We found that, as with incubation with 
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to baseline levels. Figure 3 compares the BOC-Leu-Met-CMAC 
fluorescence signal from muscle fibers of εL269F (Figure 3A), 
CS/εL269F (Figure 3B), control CS (Figure 3C), and WT mice 
(Figure 3D). Analysis of fluorescence intensity at muscle fiber end-
plate regions (Figure 3E) revealed that the increased calpain activ-
ity in εL269F muscle fibers was significantly reduced by the pres-
ence of the CS transgene (1,607 ± 79, n = 9, vs. 990.0 ± 145; n = 5; 
P < 0.05) and that calpain activity of CS (1,029 ± 83; n = 5) and 
control (WT, 819.0 ± 92; n = 8) was similar in the populations of 
fibers (P = 0.83 and P = 0.34, respectively) when compared with 
CS/εL269F. Finally, to validate the specificity and consequences 
of the measured changes in calpain activity with respect to 
known calpain substrates, we used immunoblotting with anti-
bodies for specific calpain substrates. Figure 3F shows results of 
an immunoblot for troponin-I, a calpain substrate, using muscle 
homogenates that suggests that the 24-kDa troponin-specific 
species is reduced in muscle from εL269F mice compared with 
both WT and CS/εL269F mice. Last, to ensure that the expres-
sion of the CS transgene was unchanged by coexpression of the 
εL269F transgene, we compared CS levels in WT, CS single-trans-
genic, εL269F single-transgenic, and CS/εL269F double-trans-
genic muscle by immunoblotting with anti-CS antibody. Figure 
3G demonstrates that the expression of the human CS transgene 
greatly exceeded that of endogenous mouse CS but was unaltered 
by coexpression of the εL269F transgene. These results provide 
qualitative evidence to support the conclusion of the fluorogenic 
substrate study that calpain activity is increased in εL269F muscle 
and normalized in CS/εL269F muscle.
CS improves strength in εL269F transgenic mice. To investigate wheth-
er chronic inhibition of calpain activity improved the clinical pic-
ture of SCS, we compared the strength of CS/εL269F mice with 
that of εL269F mice that did not bear the additional CS transgene 
using a grip strength paradigm (Figure 4) (9). Mice bearing the CS 
transgene alone behaved identically to WT mice both in open cage 
observation and in their performance in the grip strength experi-
ment. As shown previously, transgenic εL269F had significantly 
less grip strength when compared with nontransgenic (WT) lit-
termates (16 ± 5, n = 8, vs. 97 ± 1, n = 5; P < 0.05) (9). CS/εL269F 
double-transgenic mice had significantly improved grip strength 
when compared with εL269F littermates (67 ± 8, n = 9, vs. 16 ± 5, 
n = 8; P < 0.05), although it was not fully corrected to normal.
CS overexpression improves neuromuscular transmission in εL269F 
mice. To investigate the physiological basis for the improvement in 
strength in εL269F mice conferred by coexpression of the CS trans-
gene, we recorded electromyographic responses to repetitive nerve 
stimulation. As described previously, εL269F (Figure 5A) mice 
exhibited compound muscle action potentials (CMAPs) that were 
successively decreasing in amplitude (decremental responses) when 
evoked by repetitive stimulation at 10 Hz, a hallmark of impaired 
neuromuscular transmission (20). CS/εL269F mice (Figure 5B) had 
significantly smaller decremental responses when compared with 
εL269F mice (Figure 5E; 9.0 ± 1.3 vs. 17 ± 3.2; n = 8; P < 0.05). When 
compared with each other, neither CS mice nor nontransgenic 
control mice had significant decremental responses (Figure 5, C–E; 
3.6 ± 1.2, n = 6, vs. 3.4 ± 0.75, n = 7; P = 0.94). Thus, consistent 
with its effect on strength in εL269F mice, the CS transgene par-
tially corrected the impaired neuromuscular transmission seen in 
εL269F slow-channel transgenic mice.
The expression of CS corrects MEPC frequencies. Impaired synaptic 
function in SCS is due to a combination of effects of the mutant 
AChR on the pre- and postsynaptic determinants of successful 
neuromuscular transmission. To investigate the electrophysiologi-
cal basis for the improved neuromuscular transmission caused by 
inhibition of calpain in SCS mice, we evaluated synaptic function 
by 2-electrode voltage-clamp analysis. This in vitro technique allows 
recording of spontaneous MEPCs in excised diaphragm muscle. Fig-
ure 6, A–D, shows representative recordings of MEPCs from εL269F 
mice (Figure 6A), CS/εL269F mice (Figure 6B), CS mice bearing the 
CS transgene alone (Figure 6C, CS), and nontransgenic littermates 
(Figure 6D, WT). MEPC recordings from each genotype were ana-
lyzed with respect to 3 parameters: MEPC decay rate (Figure 6E), 
MEPC amplitude (Figure 6F), and MEPC frequency (Figure 6G).
The MEPC is the reflection of the opening of the AChR chan-
nels induced by quantal release of ACh. It has an exponential 
decay phase whose rate can be defined by the time constant (τ) 
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to the mean duration of the opening events for the AChR chan-
nels (21). Although not directly responsible for the impairment 
in neuromuscular transmission in SCS, prolonged decay phases 
(increased MEPCτ) due to point mutations in the AChR subunits 
that slow the closure of the channel are a hallmark of this disease. 
MEPC decay phase analysis is depicted in Figure 6E. The decay 
phase, MEPCτ, for εL269F mice (9.83 ± 0.98; n = 27) was signifi-
cantly prolonged compared with that for WT (2.51 ± 0.15; n = 24) 
and CS mice (2.82 ± 0.14; n = 24), consistent with previous studies 
reflecting predominant expression of the εL269F mutant AChR 
subunit over WT ε AChR subunit. The MEPCτ for CS/εL269F 
mice (8.29 ± 0.75; n = 34) was similarly prolonged compared with 
that for control mice (P < 0.05), reflecting the same preponder-
ance of mutant AChRs.
As shown previously, MEPC amplitudes of εL269F mice were 
diminished when compared with those of nontransgenic lit-
termates (Figure 6F; 1.61 ± 0.12 nA, n = 26, vs. 2.20 ± 0.10 nA, 
n = 31; P < 0.05), a change attributed to the combined effects of the 
disrupted synaptic architecture and the reduced number of end-
plate AChRs (1, 9). MEPC amplitudes (Figure 6F; 1.39 ± 0.03 nA, 
n = 71, vs. 1.61 ± 0.12 nA, n = 26; P = 0.04) were slightly smaller in 
CS/εL269F mice compared with εL269F mice, although the differ-
ence did not reach significance. However, the trend toward reduced 
MEPC amplitudes associated with the CS transgene contrasts with 
the improved synaptic function in CS/εL269F mice and implies 
that a presynaptic, positive effect on synaptic function prevails.
The frequency of spontaneous quantal release of MEPCs in 
εL269F mice was severely diminished when compared with that 
in nontransgenic littermates (Figure 6G; 0.29 ± 0.02 s–1, n = 23, vs. 
0.57 ± 0.02 s–1, n = 57; P < 0.05). This presynaptic change, also seen 
in some SCS patients (1, 2), can be attributed to the severe remod-
eling and disruption in endplate architecture in SCS and likely 
contributes significantly to impaired neuromuscular transmission 
through reduced quantal content and reduced amplitude of the 
evoked endplate potentials. In CS/εL269F mouse diaphragm, the 
MEPC frequency was increased by approximately 2-fold compared 
with that in εL269F mice (Figure 6G; 0.51 ± 0.06 s–1, n = 22, vs. 
0.29 ± 0.02 s–1, n = 23) and similar to that in normal mice. MEPC 
frequency was also approximately doubled in CS mice when com-
pared with that in nontransgenic mice (1.17 ± 0.17 s–1, n = 14, vs. 
0.57 ± 0.02 s–1, n = 57 NMJs; P < 0.05). Increased MEPC frequency 
in muscle from mice overexpressing a calpain inhibitor in mus-
cle is consistent with the demonstrated role of calpain and other 
proteases in synaptic withdrawal, based on the effect of calpain 
inhibitors in stabilizing synaptic contacts (22–25).
Molecular and structural correlates for improved strength and neuromus-
cular transmission in SCS. Reduced MEPC amplitudes in SCS and 
other NMJ disorders are attributed, in part, to a reduced number 
of AChRs at the NMJ. We previously demonstrated that endplate 
AChRs are reduced in εL269F SCS mice by determining the num-
ber of AChRs per endplate in teased brachioradialis fibers using 
[125I]αBT (10). This presumably results from the severe degenera-
tive changes (endplate myopathy) exhibited by these mice. End-
plate AChRs in CS/εL269F double-transgenic mice were slightly 
reduced but not significantly different from those in εL269F trans-







































Downloaded on August 12, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/30383
SFTFBSDIBSUJDMF
 The Journal of Clinical Investigation   http://www.jci.org   Volume 117   Number 10   October 2007 
2.22 ± 0.03 pmol; n = 8; P = 0.3). Although additional studies may 
be needed to confirm the reduced AChR number, the trend is con-
sistent with the observed trend toward reduced MEPC amplitudes 
in CS/εL269F mice compared with εL269F mice.
We investigated the structural basis for the improved MEPC fre-
quency, which had a greater impact on synaptic function than did 
the slight change in MEPC amplitudes. Using αBT conjugated 
to Texas red (RαBT) to label endplates in dissociated FDB fibers 
(4 animals/group), we measured the mean size (in μm2) of the end-
plate regions in εL269F, CS/εL269F, CS, and nontransgenic litter-
mates (WT; Figure 7). As noted in SCS patient biopsies, mean end-
plate size in SCS transgenic mice was significantly reduced when 
compared to that in nontransgenic littermates (33 ± 1.9 μm2, 
n = 248, vs. 87 ± 4.8 μm2, n = 121; P < 0.05). In contrast, endplate 
size in CS/εL269F mice was significantly increased, by approxi-
mately 2-fold, compared with that in εL269F mice (62 ± 5.4 μm2, 
n = 139, vs. 33 ± 1.9 μm2, n = 248 fibers; P < 0.05), although it 
was not fully corrected to normal. These morphological findings 
are consistent with the action of calpain inhibitors in reducing 
endplate remodeling and stabilizing neuromuscular contacts 
and correlate with the improved MEPC frequency in CS/εL269F 
mice. Curiously, although the CS mice also had increased MEPC 
frequency compared with WT, CS endplates were not larger than 
normal, suggesting that, as noted in other studies (22–25), calpain 
inhibition acts presynaptically to increase synaptic contacts.
To investigate the effect of the CS transgene on the endplate 
myopathy, we compared electron micrographs of NMJs from 
εL269F transgenic mice (Figure 8A) with those of CS/εL269F 
double-transgenic mice (Figure 8B). Several features of the end-
plate myopathy were qualitatively similar in both groups. Specifi-
cally, degenerating nuclei, mitochondria, granular debris in the 
cleft, and vacuoles appeared to be present in equal abundance. 
However, in the subjunctional area of the εL269F muscle fibers, 
the myofibrils appeared to be more consistently disorganized and 
the Z bands focally blurred (Figure 8A, arrowhead), a change also 
seen in muscle biopsies of SCS patients. To assess this finding, 
we encoded the identity of the electron micrographs and scored 
them anonymously for presence or absence of this pattern of focal 
myofibrillar degeneration (Figure 8D). We found that 86% ± 7% 
of εL269F endplates had focal myofibrillar abnormalities, com-
pared with only 30% ± 16% of CS/εL269F endplates (P < 0.05; n = 3 
mice). Myofibrillar abnormalities in CS/εL269F endplates were 
more prevalent than in controls, but were not statistically differ-
ent from either nontransgenic (4.7% ± 2.3%; n = 3; P = 0.32) and CS 
transgenic littermates (7.0% ± 4.1%; n = 4; P = 0.35). Moreover, there 
was no statistical difference in myofibrillar abnormalities identi-
fied in CS-overexpressing mice compared with nontransgenic lit-
termates. Thus, improvement of strength in CS/εL269F mice may 
result, in addition, from factors distal to AChR activation, such as 
an effect on muscle fiber contractile force.
CS does not prevent caspase activation at εL269F NMJs. Finally, to 
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hypothesized that additional proteolytic processes remained active 
in the presence of the CS transgene expression. Recently, we dem-
onstrated that activated forms of the cysteine protease caspases 
are present at the NMJ in muscle biopsies of SCS patients and in 
εL269F mice (15, 16). Here we used the caspase fluorescent label 
sulforhodamine-labeled VAD-FMK (SR-VAD-FMK) in acutely dis-
sociated FDB muscle fibers to compare caspase enzymatic activity 
in εL269F SCS and CS/εL269F mice (Figure 9, A and B, respec-
tively). Numerous εL269F mouse muscle fibers reacted when SR-
VAD-FMK was used. Labeling was localized to the region of the 
endplate in the area immediately surrounding the endplate, and 
εL269F mice and double-transgenic CS/εL269F mice appeared 
indistinguishable. To confirm that enzymatic activity correlated 
with active caspase-3 protein, we employed antisera raised against 
the cleaved form of caspase-3 and compared sections of brachiora-
dialis muscle biopsies from εL269F and CS/εL269F double trans-
genic mice (Figure 9, C and D, respectively). As with muscle from 
patients, numerous muscle fibers were labeled in and around the 
endplate region with active caspase-3 antibody. The number of 
motor endplates labeled with active caspase-3 antibody was the 
same in εL269F mice and CS/εL269F double-transgenic mice 
(Figure 9E; 54% ± 5% vs. 51% ± 5%; n = 3; P = 0.59) and increased 
roughly 4-fold when compared with that in nontransgenic litter-
mates (54% ± 5% vs. 12% ± 4%; n = 3 mice; P < 0.05). No significant 
difference was noted when comparing caspase-labeled endplates in 
CS-overexpressing and nontransgenic mice (14% ± 4% vs. 12% ± 4%, 
n = 3 mice, P = 0.76). Thus, inhibition of calpain or the presence of 
overexpressed CS protein in SCS mice does not alter the extent of 
caspase-3 activation.
%JTDVTTJPO
A clearer understanding of how disturbed AChR channel gating 
and leaky synaptic ion channels give rise to progressive impairment 
of synaptic function in SCS will enhance our ability to understand 
a variety of diseases in which synapse function is affected, includ-
ing epilepsy and Alzheimer disease. In this study we have demon-
strated that in intact, functioning synapses from mice expressing 
mutant AChRs from SCS, the calcium-activated protease calpain is 
activated and plays a role in promoting neuromuscular disease. The 
increased calpain activity is dependent on the continued activity 
of mutant AChRs and ceases after receptor blockade or axotomy, 
coincident with the disappearance of accumulated calcium. Coex-
pression of a CS transgene in the εL269F mice partially corrects 
strength and neuromuscular transmission, through a presynaptic 
protective effect on synaptic size and strength, and to a lesser extent 
focal myofibrillar degeneration. Features of the endplate myopathy, 
such as nuclear and mitochondrial degeneration, persist despite 
inhibition of calpain. These are associated with continued activa-
tion at the NMJ of a separate cascade of cysteine proteases whose 
activity is not affected by CS (26, 27). These findings suggest that 
CS improves neuromuscular transmission in εL269F mice predom-
inantly by strengthening the synaptic contacts, rather than through 
correcting the postsynaptic side of the NMJ. Calpain inhibition 
may also provide some local protection of contractile apparatus.
The calcium-activated neutral protease calpain is a cysteine 
protease of ubiquitous tissue distribution and broad subcellular 
localization (28–30). In muscle, calpain is immunologically local-
ized to endomysial collagen fibrils, basal lamina, sarcolemma, 
Z bands, and NMJs, as well as the extracellular space (29, 31). 
Calpains exist in multiple subtypes, differing in calcium sensi-
tivity and function, and are involved in several cellular signaling 
pathways, myoblast fusion, cytoskeletal protein turnover, neurite 
outgrowth, and growth cone turning in development (26, 32–35). 
In the neuromuscular system, during development and reinnerva-
tion, calpain and possibly other proteases play a prominent role in 
synaptic remodeling and stabilization of neuromuscular contacts, 
a process that is highly reminiscent of that observed in SCS (24, 25, 
32, 36–39). Calpain activation may also contribute to the patho-
genesis of stroke, myocardial infarction, Alzheimer disease, and 
muscle disorders such as muscular dystrophy. mdx mice, which 
bear mutations in the murine form of dystrophin, have a muscle 
disease similar to Duchenne muscular dystrophy (40). mdx mice 
bearing the same human CS transgene used in this study have less 
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Elevated calpain activity in εL269F mice appears either as a dif-
fuse increase or as intense regions of calpain activity located near the 
NMJ. The focal activity of calpain is consistent with previous find-
ings of histochemically detectable deposits of calcium at NMJs in 
muscle biopsies from SCS patients or transgenic mice or localized 
increases detected in SCS muscle in real time using calcium-sensitive 
dyes in vitro (1, 9–11, 15, 16). The rapid disappearance of elevated cal-
pain activity after axotomy or AChR blockade demonstrates that the 
increased calpain activity is dynamic and directly related to ongoing 
activity of mutant AChRs rather than to a compensatory response.
The improvement in strength and neuromuscular transmission 
seen in εL269F transgenic mice expressing CS appears to result 
predominantly from a strengthening of synaptic connections, 
leading to normalized endplate size and MEPC frequency, rather 
than a protective effect on AChRs. Rather than being increased, 
both MEPC amplitude and AChR number were normal or slightly 
reduced by overexpression of CS, although the slight effect on 
MEPCs did not negatively affect the presynaptic improvement 
in neuromuscular transmission. Reduced MEPC amplitudes and 
AChR density in CS/εL269F mice may relate to the continued 
activity of other proteases, such as the caspases, despite the expres-
sion of CS. Also, maintenance of synaptic contacts due to inhibi-
tion of nerve terminal retraction (see below) may protect compro-
mised synaptic regions that would otherwise be eliminated and 
increase the pool of smaller-amplitude MEPCs.
The increase in synaptic strength in SCS mice bearing the CS 
transgene is consistent with the recognized participation of calci-
um-activated proteases in nerve terminal elimination of polyneu-
ronal innervation, in stabilizing neuromuscular contacts, and in 
remodeling of the NMJ. These processes are modulated by protease 
inhibitors that appear to protect calpain targets in the muscle and 
nerve cytoskeleton and basal lamina (22–25). Given the prominent 
activity of calpain in mouse SCS muscle fibers, it is not surprising 
that this enzyme participates in the NMJ remodeling recognized 
in SCS. The current model expands on those of previous protease 
inhibitor studies, as it involves a chronic, degenerative neuromus-
cular disease and direct transgenic targeting of calpastatin expres-
sion to muscle. Nevertheless, the same functional targets appear 
to be protected. This is consistent with the observation in fusing 
myoblasts that muscle-derived calpain is exteriorized and acts on 
extracellular matrix components, such as fibronectin (33). Last, the 
ultrastructural and immunoblot studies also point to some pro-
tection by calpain inhibition of myofibrillar structural proteins, 
recognized targets of calpains, indicating the action and potential 
role of this enzyme in muscle disease (41–43).
Calpain inhibition by CS expression did not improve several sig-
nificant features of the endplate myopathy in SCS mice, including 
degenerating nuclei and dilated mitochondria. A second family of 
cysteine proteases, the caspase proteases, makes up a cascade of 
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involved in a complex cross-talk with the calpains (44). Caspases 
are also activated at the NMJ in SCS, and organellar degeneration 
resolves in close parallel to the disappearance of caspase activity 
after axotomy (15, 16). However, activated caspases persist at the 
NMJ in SCS after calpain inhibition by CS (Figure 9). Studies have 
pointed to a role for calpain itself in either the activation or inac-
tivation of caspases in different settings (44, 45). CS is also a sub-
strate for caspase-3, and its proteolysis by caspases in SCS might 
be expected to allow for greater increases in calpain activation (44). 
Our findings showing inhibition of calpain with overexpressed CS 
demonstrate that calpain can be effectively inhibited while caspase-3 
appears unaffected. These studies demonstrate that the calpain 
and caspase protease systems play predominant roles in the patho-
genesis of the SCS. Therapies designed to chronically reduce exces-
sive calpain and caspase activities may be useful in the treatment 
of the SCS and related excitotoxic and muscle disorders.
.FUIPET
Animals and reagents. The generation, characterization, and screening of 
εL269F slow-channel transgenic mice (εL269F mice) and mice expressing 
human CS has been reported previously (9, 19, 46). εL269F transgenic mice, 
line 14, express high levels, approximately 1,000-fold over endogenous WT 
mouse ε subunit, of the mouse AChR ε subunit mRNA bearing an εL269F 
mutation under the control of the muscle creatinine kinase promoter 
(MCK). CS-transgenic mice, line 70.7, were derived from a construct that 
expresses human CS under the control of the human β-actin promoter and 
express CS protein at a level about 30-fold greater than endogenous pro-
tein. All breeding, screening, and experimental procedures were approved 
by the Institutional Animal Care and Use Committee of the University of 
Minnesota. Double-transgenic mice bearing both transgenes were detected 
in F1 litters by PCR analysis of tail DNA using transgene-specific primers 
and were viable. Control mice (WT) consisted of hybrid littermates or age-
matched transgene-negative mice. Age-matched mice, approximately 2–8 
months, were used for all studies.
RαBT and BOC-Leu-Met-CMAC, (prepared as a 10-mM stock in DMSO) 
were obtained from Molecular Probes (Invitrogen). SR-VAD-FMK was 
acquired from BIOMOL International. N-acetyl-Leu-Leu-Nle-CHO (CP1) 
was purchased from Calbiochem. Dulbecco’s modified Eagle’s medium 
without phenol red (DMEM) and Hanks solution without phenol red 
(Hanks) were from Invitrogen. Mouse monoclonal troponin-I (skeletal) 
antibody was from Abcam. Rabbit polyclonal anti-Bax and goat polyclonal 
troponin-I were purchased from Santa Cruz Biotechnology Inc. Secondary 
antibodies conjugated to HRP and ECL reagents were from Amersham. 
Anti-goat secondary antibody conjugated to HRP was purchased from 
Jackson Immunoresearch Laboratories Inc. Nitrocellulose and PVDF 
membranes were from Bio-Rad. Protease inhibitor cocktail Complete 
Mini tablets (EDTA-free) were from Roche. BCA protein assay reagents 
were from Pierce. All others were purchased from Sigma-Aldrich unless 
otherwise specified.
Animals were sedated as needed for surgery using Avertin (250 mg/kg 
i.p.) (47) and euthanized immediately after the surgery. Strength testing by 
wire-hang test, measurement of AChR density by [125I]αBT binding, and 
electromyography were performed as described previously (8, 9). Briefly, the 
wire-hang test was performed by timing the period the animals were able 
to hang suspended gripping a wire by their forepaws. AChR density was 
determined as the ratio of [125I]αBT binding on labeled muscle bundles to 
the number of endplates in the fibers. Electromyography was performed on 
anesthetized animals by recording CMAPs using subcutaneous electrodes 
placed over heel and at toe and evoked by direct stimulation of the sciatic 
nerve. Voltage-clamp analysis was performed in excised diaphragm in vitro 
using sharp electrodes inserted into individual muscle fibers, 1 for record-
ing voltage and 1 for injecting current. The signals are amplified and digi-
tized using a voltage-clamp amplifier and the software program pCLAMP 
(Molecular Devices). Histochemical (tissue) stains for acetylcholinesterase 
and GBHA were described previously (48, 49). Caspase-3 immunostaining 
and microscopy were performed as previously described (16). Voltage-clamp 
analyses of MEPCs were performed exactly as described previously (8).
Axotomy and AChR blockade. The left sciatic nerve was exposed through 
a 5-mm incision in the upper thigh in anesthetized animals, and a 2-mm 
portion was excised. Surgical incisions were closed with wound clips, and 
animals were observed for recovery and normal food and water intake after 
surgery. For αBT blockade of AChRs, the ventral hind paw was injected 
subcutaneously alongside the FDB muscle with 10–25 μl of a solution 
of 1.7 μM αBT in lactated Ringer’s solution (LR) (28-gauge needle) and 
flushed out with LR after 20 minutes. FDB muscles were removed after 24 
hours for calpain assay.
Muscle fiber dissociation and labeling. The hind-limb FDB muscles were 
aseptically exposed and excised, and fibers were dissociated by incubation 
in 400 μl digestion solution (3% collagenase, 1% hyaluronidase, and 5% 
BSA in DMEM), at 37°C with 5% CO2 for 1.5 hours. To avoid muscle fiber 
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gravity sedimentation in 0.7 ml PCR tubes for 20 minutes and the super-
natants discarded. Controls consisted of contralateral dissociated FDB 
muscle fiber suspensions incubated in 400 μl 80-μM CP1 or 1% DMSO 
(vehicle) in DMEM at 37°C with 5% CO2 for 20 minutes.
Fiber bundles were transferred to a labeling cocktail consisting of 10 
μM BOC-Leu-Met-CMAC, 0.3 μM RαBT, 1 μM ATP, and 5% horse serum 
in Hanks solution without phenol red (Invitrogen), and, after removal of 
tendinous material, triturated ×4 with a wide bore polyethylene plastic 
pipette. The fiber suspensions were washed once in 700 μl Hanks prior to 
mounting (in Hanks) on glass slides.
Staining with SR-VAD-FMK was performed after dissociation as 
described above and according to the manufacturer’s instructions, except 
that the fibers were washed extensively in a diffusion chamber overlaid 
with a micromesh with Hanks prior to visualizing.
Western immunoblotting. FDB whole muscle or muscle fiber preparations 
were disrupted in frosted glass homogenizers in 5 volumes of protein 
extraction buffer thoroughly while on ice (20 mM phosphate buffer, pH 
7.8, 10 mM EDTA, 10 mM EGTA, plus 1 tablet of protease inhibitor cock-
tail). Crude protein concentration was estimated using the BCA protein 
assay, and samples were heat treated with standard loading buffer under 
reducing conditions; loaded equally at 25 μg/well across all lanes; and elec-
trophoresed on 10%–20% Bio-Rad Ready Gels. Sister gels were transferred 
to either nitrocellulose (for goat and rabbit primaries) or PVDF (for mouse 
primaries) membranes for 1 hour at 75 V. After blocking in 5% milk-TBS, 
primary antibody dilutions were prepared in 5% milk-TBS and were 1:500 
for goat anti–troponin-I, 1:5,000 for mouse monoclonal anti–troponin-I, 
1:2,000 for rabbit polyclonal anti-Bax (data not shown). Monoclonal anti-
CS antibody (Takara Biomedicals) was used at 1:1,000. Secondary antibod-
ies were prepared in 1% milk-TBS; the dilutions were 1:5,000 (or 1:10,000) 
for anti-mouse and -rabbit and 1:10,000 for anti-goat. Membranes were 
activated with ECL Chemiluminescence Detection System (Pierce Biotech) 
or ChemiGlow (Alpha-InnoTec), according to the manufacturer’s instruc-
tions, and exposed to Kodak X-OMAT or Pierce CL-Xposure film. As a 
loading control, a sister gel of the same homogenates was used to detect the 
55-kDa species corresponding to IgG heavy chain (Figure 3F, upper panel). 
Immunoblotting for CS was similar, except that tibialis anterior muscles 
were homogenized in sample buffer containing 80 mM Tris-HCl (pH 6.8), 
2% SDS, 10% glycerol, 100 mM DTT, and protease inhibitor cocktail, then 
boiled and centrifuged at 15,000 g, and supernatants were subjected to 10% 
PAGE. Because of the high levels of transgene expression compared with 
endogenous mouse CS protein, εL269F single-transgenic and WT samples 
were loaded at 40 μg/well, while εL269F/CS double-transgenic and CS sin-
gle-transgenic samples were loaded at 4 μg/well. Ponceau red staining for 
the actin band was used as loading control (Figure 3G, lower panel).
Microscopy and image analysis. Microscopy was performed immediately 
after mounting, with a maximum latency of 1 hour. Images (72 dpi) were 
collected utilizing an Olympus IX70 inverted microscope at ×10 power 
equipped with a C4742-95 Hamamatsu digital camera head and analyzed 
with imaging software (Metafluor; Universal Imaging Corp.). To visualize 
BOC-Leu-Met-CMAC fluorescence, the fiber mounts were excited with a 
UV lamp at 355 nm, and the 465-nm image emissions were collected for 70 
ms with a standard DAPI filter cube. For RαBT visualization of the AChRs 
found at the endplates, fibers were excited at 528.7 nm, and emissions were 
collected at 550 nm for 300 ms using a standard rhodamine band pass 
filter set. Forty to 60 intact fibers identified by systematic scanning were 
recorded per experimental group. For each fiber, the area corresponding 
to the endplate region (as localized with RαBT) was marked by placement 
of a circle on the image with a diameter matching that of the fiber. The 
average fluorescence intensity for BOC-Leu-Met-CMAC in this area was 
recorded using an image analysis program (Metafluor) and exported to 
a spreadsheet file (Excel; Microsoft) for statistical analysis. Endplate (as 
determined by RαBT staining) cross-sectional area was estimated utilizing 
a ×10 objective and Hamamatsu camera capturing 72-dpi images, in which 
the measure tool in the image processing program, Photoshop (Adobe), 
detected a pixel width of 2.7 μm for such images, which when squared was 
7.3 μm2. Therefore, the total number of pixels captured by Metafluor at the 
threshold divided by 7.3 was reported as the cross-sectional area.
For SR-VAD-FMK visualization, the images were first recorded under 
visual light illumination with Metafluor for 50 ms through a ×40 oil immer-
sion objective. Immediately afterward, the same field of view was excited at 
528.7 nm, and 550-nm emissions were recorded through a standard rhoda-
mine band pass filter set. For display, merged montages of the Metafluor 
images were prepared using a graphics program (Photoshop; Adobe).
Statistics. For comparison of 2 groups, data were compared using 2-tailed 
Student’s t test when assuming unequal variances. For comparison of 3 or 
more groups, data were analyzed using ANOVA followed by Bonferroni 
and Dunn’s post-hoc analysis. Data are reported as mean ± SEM. Overall 
experimental significance was assigned for individual comparisons when 
P was less than 0.0083, with a 95% confidence level (overall experimental 
significance, P < 0.05). A contralateral comparison strategy was applied 
where applicable, so one could compare treated and untreated sides within 
the same animal to eliminate concerns of individual genetic variation.
Note added in proof. Chen et al. recently reported that calpain, acti-
vated by cholinergic stimulation and inhibited by rapsyn, drives 
CDK5 activity, which disperses AChR clusters in developing mus-
cle fibers (50). This finding identifies additional NMJ proteins that 
may be involved in SCS pathogenesis.
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